The Evolution of TKIs in ROS1+ NSCLC - Episode 3

Selecting a TKI in ROS1+ NSCLC Management

,

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

EP. 1: The Prevalence of ROS1 Fusions in Advanced NSCLC
EP. 2: Treatment Sequencing Decisions in ROS1+ NSCLC
Now Viewing
EP. 3: Selecting a TKI in ROS1+ NSCLC Management
EP. 4: Addressing CNS Involvement in ROS1+ NSCLC
EP. 5: Pooled Data for Taletrectinib in ROS1+ NSCLC
EP. 6: Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC
EP. 7: Novel Treatment Approaches Under Investigation in ROS1+ NSCLC

Related Content:

Penn MedicineThe Evolution of TKIs in ROS1+ NSCLCOncLive News Network®Lung Cancer
VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD
PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors
Dr Jänne on the Design of the FLAURA2 Trial of Osimertinib Plus Chemotherapy in EGFR+ NSCLC